Compare FGI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FGI | PRPO |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | 426 | N/A |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 42.0M |
| IPO Year | 2021 | 2000 |
| Metric | FGI | PRPO |
|---|---|---|
| Price | $8.02 | $22.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 39.9K | ★ 120.8K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | $3.45 | $233.72 |
| Revenue Next Year | $5.39 | $22.61 |
| P/E Ratio | $45.12 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $3.14 | $16.40 |
| 52 Week High | $19.93 | $33.63 |
| Indicator | FGI | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | N/A |
| Support Level | $6.63 | N/A |
| Resistance Level | $10.30 | N/A |
| Average True Range (ATR) | 0.82 | 0.00 |
| MACD | -0.20 | 0.00 |
| Stochastic Oscillator | 18.64 | 0.00 |
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, it generates the majority of its revenue from the United States, followed by Canada and Europe.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.